Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.86 +3.2%	$2.52	$1.78 ▼ $8.56	$58.13M	0.77	110,500 shs	132,946 shs
IPHA Innate Pharma	$2.14 -2.1%	$1.94	$1.29 ▼ $3.51	$200.57M	0.22	13,103 shs	7,297 shs
JSPR Jasper Therapeutics	$3.11 +2.6%	$4.16	$2.27 ▼ $26.05	$45.52M	2.7	312,765 shs	323,724 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	+3.25%	+24.89%	+3.62%	+34.91%	-55.66%
IPHA Innate Pharma	-2.06%	-2.06%	+18.61%	+0.95%	-2.51%
JSPR Jasper Therapeutics	+2.64%	+26.94%	-7.16%	-36.92%	-82.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership
ADVM Adverum Biotechnologies	3.9028 of 5 stars	3.4	3.0	4.8	2.4	0.8
IPHA Innate Pharma	2.2421 of 5 stars	3.7	2.0	0.0	2.4	1.7
JSPR Jasper Therapeutics	2.9622 of 5 stars	4.3	4.0	0.0	1.0	1.7

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.75	Moderate Buy	$19.75	590.56% Upside
IPHA Innate Pharma	3.33	Buy	$11.00	415.22% Upside
JSPR Jasper Therapeutics	2.60	Moderate Buy	$28.75	824.44% Upside

Current Analyst Ratings Breakdown

Latest JSPR, ADVM, and IPHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$29.00 ➝ $25.00
8/13/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00
7/28/2025	IPHA Innate Pharma	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
7/8/2025	JSPR Jasper Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00
7/8/2025	JSPR Jasper Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$70.00 ➝ $12.00
7/8/2025	JSPR Jasper Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $20.00
7/8/2025	JSPR Jasper Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/7/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
7/7/2025	JSPR Jasper Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	60.00	N/A	N/A	($0.96) per share	-2.98
IPHA Innate Pharma	$21.77M	9.04	N/A	N/A	$0.11 per share	19.41
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$1.56 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$130.93M	-$7.85	N/A	N/A	N/A	N/A	-297.29%	-101.40%	11/3/2025 (Estimated)
IPHA Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
JSPR Jasper Therapeutics	-$71.27M	-$5.24	N/A	N/A	N/A	N/A	-172.28%	-128.34%	N/A

Latest JSPR, ADVM, and IPHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	JSPR Jasper Therapeutics	-$1.20	-$1.74	-$0.54	-$1.74	N/A	N/A
8/12/2025	Q2 2025	ADVM Adverum Biotechnologies	-$2.24	-$2.34	-$0.10	-$2.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	1.54	3.57
IPHA Innate Pharma	2.52	2.60	2.60
JSPR Jasper Therapeutics	N/A	2.10	4.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
IPHA Innate Pharma	0.16%
JSPR Jasper Therapeutics	79.85%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
IPHA Innate Pharma	31.89%
JSPR Jasper Therapeutics	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.98 million	19.73 million	Optionable
IPHA Innate Pharma	220	92.18 million	62.79 million	Not Optionable
JSPR Jasper Therapeutics	20	15.02 million	14.33 million	Optionable

JSPR, ADVM, and IPHA Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

August 16 at 10:00 AM | prnewswire.com

BTIG Keeps Their Buy Rating on Jasper Therapeutics (JSPR)

August 15 at 4:30 PM | theglobeandmail.com

Jasper Therapeutics price target lowered to $25 from $29 at UBS

August 15 at 4:30 PM | msn.com

Jasper Therapeutics reports Q2 EPS ($1.74), consensus ($1.33)

August 14 at 10:49 AM | msn.com

Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14 at 10:49 AM | finanznachrichten.de

Jasper Reports Wider Loss in Fiscal Q2

August 14 at 10:49 AM | aol.comA

Jasper Therapeutics Reports Promising Q2 2025 Results

August 14 at 10:49 AM | msn.com

Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13 at 4:19 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

August 13 at 11:55 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

August 11, 2025 | prnewswire.com

Jasper Therapeutics (JSPR) Expected to Announce Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

August 9, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

August 6, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

August 1, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

July 31, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

July 28, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

July 27, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

July 23, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

July 22, 2025 | prnewswire.com

Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of "Moderate Buy" from Analysts

July 20, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

July 18, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR, ADVM, and IPHA Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.86 +0.09 (+3.25%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.77 -0.09 (-3.29%)

As of 08/15/2025 07:56 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Innate Pharma NASDAQ:IPHA

$2.13 -0.05 (-2.06%)

As of 08/15/2025 03:55 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Jasper Therapeutics NASDAQ:JSPR

$3.11 +0.08 (+2.64%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.06 -0.05 (-1.74%)

As of 08/15/2025 06:15 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time